<DOC>
	<DOC>NCT00386685</DOC>
	<brief_summary>The primary objective of the study is to assess the activity of XRP9881 in combination with trastuzumab. The secondary objectives are safety and pharmacokinetic interaction</brief_summary>
	<brief_title>XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Metastatic breast cancer (MBC) HER2 (Human Epidermal Growth Factor Receptor 2) positive: FISH (Fluorescent In Situ Hybridization) positive or IHC (Immunohistochemistry) 3+ Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Adequate organs functions More than one previous chemotherapy regimen for metastatic disease Cardiac dysfunction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Breast</keyword>
	<keyword>metastatic breast cancer</keyword>
</DOC>